Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus

Refractory status epilepticus (RSE) and superrefractory status epilepticus (SRSE) pose a difficult clinical challenge. Multiple cerebral receptor and transporter changes occur with prolonged status epilepticus leading to pharmacoresistance patterns unfavorable for conventional antiepileptics. In particular, n-methyl-d-aspartate (NMDA) receptor upregulation leads to glutamate mediated excitotoxicity. Targeting these NMDA receptors may provide a novel approach to otherwise refractory seizures. Ketamine has been utilized in RSE. Recent systematic review indicates 56.5% and 63.5% cessation in seizures in adults and pediatrics, respectively. No complications were described. We should consider earlier implementation of ketamine or other NMDA receptor antagonists, for RSE. Prospective study of early implementation of ketamine should shed light on the role of such medications in RSE.

[1]  F. Zeiler,et al.  The ketamine effect on intracranial pressure in nontraumatic neurological illness. , 2014, Journal of critical care.

[2]  Dieter Schmidt,et al.  Drug treatment of epilepsy in adults , 2014, BMJ : British Medical Journal.

[3]  F. Zeiler,et al.  NMDA Antagonists for Refractory Seizures , 2014, Neurocritical Care.

[4]  F. Zeiler,et al.  The Ketamine Effect on ICP in Traumatic Brain Injury , 2014, Neurocritical Care.

[5]  G. Testylier,et al.  Treatment of Status Epilepticus with Ketamine, Are we There yet? , 2013, CNS neuroscience & therapeutics.

[6]  E. Wijdicks,et al.  Refractory status epilepticus: new insights in presentation, treatment, and outcome , 2013, Neurological research.

[7]  S. Moss,et al.  Possible alterations in GABAA receptor signaling that underlie benzodiazepine‐resistant seizures , 2012, Epilepsia.

[8]  J. Britton,et al.  Predictors of outcome in refractory status epilepticus. , 2012, JAMA neurology.

[9]  D. L. Oliveira,et al.  Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats , 2012, Brain Research.

[10]  S. Shorvon,et al.  The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. , 2012, Brain : a journal of neurology.

[11]  Paul M. Vespa,et al.  Guidelines for the Evaluation and Management of Status Epilepticus , 2012, Neurocritical Care.

[12]  G. B. Young,et al.  Status Epilepticus: A Review, With Emphasis on Refractory Cases , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[13]  Simon Shorvon,et al.  The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. , 2011, Brain : a journal of neurology.

[14]  B. Adibeik.  Status Epilepticus: A Review , 2008 .

[15]  C. Wasterlain,et al.  Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs , 2008, Epilepsia.

[16]  R. Macdonald,et al.  Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. , 2008, Journal of neurophysiology.

[17]  J. Kapur,et al.  A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation , 2008, Epilepsia.

[18]  W. Löscher.  Mechanisms of drug resistance in status epilepticus , 2007, Epilepsia.

[19]  R. N. Takahashi,et al.  Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats , 2007, Neuroscience Letters.

[20]  J. Mikler,et al.  Protective effects of S+ ketamine and atropine against lethality and brain damage during soman-induced status epilepticus in guinea-pigs. , 2007, Toxicology.

[21]  R. M. Freitas,et al.  Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus , 2006, Neuroscience Letters.

[22]  M. Bullock,et al.  The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. , 2005, Journal of neurotrauma.

[23]  D. Fujikawa,et al.  Prolonged seizures and cellular injury: Understanding the connection , 2005, Epilepsy & Behavior.

[24]  A. Vezzani,et al.  Brain Inflammation in Epilepsy: Experimental and Clinical Evidence , 2005, Epilepsia.

[25]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[26]  W. Löscher,et al.  N-methyl-d-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy , 2003, Neuroscience.

[27]  Jan Claassen,et al.  Refractory status epilepticus: frequency, risk factors, and impact on outcome. , 2002, Archives of neurology.

[28]  R. Bullock,et al.  First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (CGS 19755) in patients with severe head injury. , 1999, Journal of neurotrauma.

[29]  J. Olney,et al.  N-Methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Fujikawa.  Neuroprotective Effect of Ketamine Administered After Status Epilepticus Onset , 1995, Epilepsia.

[31]  J. Olney,et al.  Neuronal Vacuolization and Necrosis Induced by the Noncompetitive N-methyl-d-aspartate (NMDA) Antagonist MK(+)801 (Dizocilpine Maleate): A Light and Electron Microscopic Evaluation of the Rat Retrosplenial Cortex , 1993, Experimental Neurology.

[32]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.